Get alerts on this situation
We’ll email you as it develops, and you can follow the whole thread from day one.
Unsubscribe anytime.
[SITUATION] · [ACTIVE]
2 clusters · 7 sources · 3 days · First seen · Last updated
Categories: HEALTH
ALS early detection biomarker research – validation
Entities: Nature Medicine · Tofersen · University of Utah School of Medicine · Neurofilament light chain (NEFL) · Cas12a2 enzyme
Overview
In July 2026 a U.S. NIH‑funded team reported in *Nature Medicine* that a panel of 19 blood proteins can anticipate the clinical onset of amyotrophic lateral sclerosis about 1.6 years ahead. The finding came from 516 plasma samples collected over 18 years from 137 genetically at‑risk participants in the Pre‑fALS cohort and was presented as a potential tool for preventive trial enrollment, though it was not yet a diagnostic test.
A follow‑up report later in the month confirmed the panel’s predictive accuracy, showing it outperformed the previously strongest marker (NEFL) and could estimate timing of phenoconversion. Researchers stressed that further validation and adaptation to routine laboratory methods are required before clinical use, highlighting an emerging window for early‑intervention strategies in ALS.
Later in July, scientists at the University of Miami replicated the approach, applying artificial‑intelligence analysis to the same Pre‑fALS dataset and reaffirming the 19‑protein panel’s ability to forecast disease onset with an average error of about 1.6 years. Independent validation using data from the UK Biobank confirmed the pattern’s broader applicability. The team noted that the assay remains experimental and is being explored as a screening tool to time enrolment in trials of the experimental drug tofersen, which may delay or prevent onset when given before symptoms appear.
The combined reports underscore a converging effort to move from reactive ALS management toward proactive, biomarker‑driven trial design, while emphasizing the need for further validation and clinical‑grade assay development.
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [● 5 SOURCES] A panel of 19 blood proteins can predict ALS onset in gene carriers. (Researchers at the University of Miami)
- [● 5 SOURCES] The study analyzed over 5,000 proteins in 516 plasma samples from 137 participants of the Pre‑fALS study. (Researchers)
- [● 5 SOURCES] Findings were validated using data from the UK Biobank. (Study authors)
- [● 5 SOURCES] Artificial‑intelligence methods were used to select the optimal protein combination. (Researchers)
- [● 5 SOURCES] The study was published in Nature Medicine in July 2026. (Publication record)
- [● 5 SOURCES] The protein panel is not yet ready for clinical use and requires further validation. (Authors)
- [● 4 SOURCES] Researchers are testing whether the drug tofersen can delay ALS if started before symptoms appear. (Study authors)
Timeline
-
5 days ago
[HEALTH] 5 sourcesALS Blood‑Protein Panel Predicts Disease Onset Years EarlyA University of Miami study identified a 19‑protein blood panel that predicts ALS onset in gene carriers with ~1.6‑year accuracy, validated by UK Biobank data, but not yet ready for clinical use.
-
8 days ago
[HEALTH] 2 sourcesNIH ALS blood biomarker panel and CRISPR Cas12a2 enzyme signal new disease‑targeting therapiesNIH‑backed study finds a 19‑protein blood panel predicts ALS onset; CRISPR Cas12a2 enzyme may enable selective tumor‑cell destruction, hinting at new disease‑targeting therapies.
Sources
bursahakimiyet.com.tr · digitalphablet.com · knowridge.com · liberoquotidiano.it · limpe.it · memesita.com · studyfinds.org
This summary has been updated 1 time: see revision history